Keywords: Gout drug market, Takeda, Uloric, Savient, Krystexxa, Rheumatologists

Takeda’s Uloric making inroads in moderate-to -severe gout patients, but allopurinol has vast market share lead

Article | 04 September 2011

Most surveyed rheumatologists, nephrologists and primary care physicians cite increased use of Uloric (febuxostat), from Japan’s largest drugmaker ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in